Prostate cancer, a leading cause of cancer-related deaths worldwide, principally occurs in over 50-year-old men. Nowadays there is urgency to discover biomarkers alternative to prostate-specific antigen, as it cannot discriminate patients with benign prostatic hyperplasia from clinically significant forms of prostatic cancer. In the present paper, 32 benign prostatic hyperplasia and 41 prostatic cancer urine samples were collected and analyzed. Polar and positively charged metabolites were therein investigated using an analytical platform comprising an up to 40-fold analyte enrichment step by graphitized carbon black solid-phase extraction, HILIC separation, and untargeted high-resolution mass spectrometry analysis. These classes of compounds are often neglected in common metabolomics experiments even though previous studies reported their significance in cancer biomarker discovery. The complex metabolomics big datasets, generated by the UHPLC-HRMS, were analyzed with the ROIMCR procedure, based on the selection of the MS regions of interest data and their analysis by the Multivariate Curve-Resolution Alternating Least Squares chemometrics method. This approach allowed the resolution and tentative identification of the metabolites differentially expressed by the two data sets. Among these, amino acids and carnitine derivatives were tentatively identified highlighting the importance of the proposed methodology for cancer biomarker research. © 2021 Elsevier B.V.
Untargeted metabolomics of prostate cancer zwitterionic and positively charged compounds in urine / Cerrato, Andrea; Bedia, Carmen; Capriotti, Anna Laura; Cavaliere, Chiara; Gentile, Vincenzo; Maggi, Martina; Montone, Carmela Maria; Piovesana, Susy; Sciarra, Alessandro; Tauler, Roma; Laganà, Aldo. - In: ANALYTICA CHIMICA ACTA. - ISSN 0003-2670. - 1158:(2021), p. 338381. [10.1016/j.aca.2021.338381]
Untargeted metabolomics of prostate cancer zwitterionic and positively charged compounds in urine
Cerrato, Andrea;Capriotti, Anna Laura
;Cavaliere, Chiara;Gentile, Vincenzo;Maggi, Martina;Montone, Carmela Maria;Piovesana, Susy;Sciarra, Alessandro;Laganà, Aldo
2021
Abstract
Prostate cancer, a leading cause of cancer-related deaths worldwide, principally occurs in over 50-year-old men. Nowadays there is urgency to discover biomarkers alternative to prostate-specific antigen, as it cannot discriminate patients with benign prostatic hyperplasia from clinically significant forms of prostatic cancer. In the present paper, 32 benign prostatic hyperplasia and 41 prostatic cancer urine samples were collected and analyzed. Polar and positively charged metabolites were therein investigated using an analytical platform comprising an up to 40-fold analyte enrichment step by graphitized carbon black solid-phase extraction, HILIC separation, and untargeted high-resolution mass spectrometry analysis. These classes of compounds are often neglected in common metabolomics experiments even though previous studies reported their significance in cancer biomarker discovery. The complex metabolomics big datasets, generated by the UHPLC-HRMS, were analyzed with the ROIMCR procedure, based on the selection of the MS regions of interest data and their analysis by the Multivariate Curve-Resolution Alternating Least Squares chemometrics method. This approach allowed the resolution and tentative identification of the metabolites differentially expressed by the two data sets. Among these, amino acids and carnitine derivatives were tentatively identified highlighting the importance of the proposed methodology for cancer biomarker research. © 2021 Elsevier B.V.File | Dimensione | Formato | |
---|---|---|---|
Cerrato_Untargeted_2021.pdf
solo gestori archivio
Note: https://doi.org/10.1016/j.aca.2021.338381
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
2.17 MB
Formato
Adobe PDF
|
2.17 MB | Adobe PDF | Contatta l'autore |
Cerrato_Untargeted _2020postprint.pdf
Open Access dal 13/03/2022
Note: https://doi.org/10.1016/j.aca.2021.338381
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Creative commons
Dimensione
2.29 MB
Formato
Adobe PDF
|
2.29 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.